Pricing Log in Create free account
Friday 6 November 2026 Export CGON’s income statement to Excel — free account

CG Oncology, Inc.

CGON Healthcare Biotechnology

CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.

Revenue
−3.72%
EPS
−12.3%
Free cash flow
−25.2%
Total debt
0.00%

Quarter to September 2026, against a year earlier

76.08 11.28 +17.41%
Market cap
$5.7B
P/E
0.0×
Fwd P/E
−19.5×
Dividend yield
—
F-score
2/9
Altman Z
49.04
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

CG Oncology, Inc. (CGON) Debt to equity

Alert me on Debt to equity

CG Oncology, Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 0.0×, down 0.0× from fiscal 2025 (0.0×). That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.

Debt to equity, annual

Embed this chart

Annual newest first

Period Debt to equity Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 −0.2× —

Quarterly newest first

Period Debt to equity Change
Sep 2026 0.0× 3.45%
Jun 2026 0.0× 7.41%
Mar 2026 0.0× (32.50%)
Dec 2025 0.0× (9.09%)
12 more quarters

Debt to equity against peers

Company Debt to equity
PTCT PTC Therapeutics, Inc. compare −14.9×
MIRM Mirum Pharmaceuticals, Inc. compare −13.5×
BLTE Belite Bio, Inc. Sponsored ADR compare 0.0×
MANE Veradermics Incorporated compare 0.0×
IMVT Immunovant, Inc. compare 0.0×
KOD Kodiak Sciences Inc. compare 0.0×
CGON CG Oncology, Inc. 0.0×
LGND Ligand Pharmaceuticals Incorporated compare 0.7×
SRRK Scholar Rock Holding Corporation compare 0.8×
Biotechnology industry median 0.0×
Healthcare sector median 0.0×
Market median 0.1×

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

More on CGON